Dan Puckett Biography and Net Worth

CFO of Shockwave Medical

Dan joined Shockwave Medical in April 2016 as the company’s Chief Financial Officer. Most recently, Dan served as CFO for Counsyl, a venture-backed DNA testing and genetic counseling company.

From 2011 to 2015, Dan served as CFO for Ariosa Diagnostics, a molecular diagnostics company (acquired by Roche in 2015). Dan came to Ariosa from Forest Laboratories where he served as Executive Director, Operations of Cerexa, a Forest Laboratories subsidiary. Prior to Cerexa, Dan held senior finance and operations positions at Affymetrix, Inc., AOL and BHP Billiton Ltd.

Dan earned his MBA from the University of San Francisco and a BA degree in Accounting from Washington State University.

What is Dan Puckett's net worth?: The estimated net worth of Dan Puckett is at least $9.28 million as of February 1st, 2024. Mr. Puckett owns 27,732 shares of Shockwave Medical stock worth more than $9,283,287 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Puckett may own. Learn More about Dan Puckett's net worth.
How do I contact Dan Puckett?: The corporate mailing address for Mr. Puckett and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at [email protected]. Learn More on Dan Puckett's contact information.
Has Dan Puckett been buying or selling shares of Shockwave Medical?: Dan Puckett has not been actively trading shares of Shockwave Medical during the last ninety days. Most recently, Dan Puckett sold 3,406 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a transaction totalling $782,562.56. Following the completion of the sale, the chief financial officer now directly owns 27,732 shares of the company's stock, valued at $6,371,704.32. Learn More on Dan Puckett's trading history.
Who are Shockwave Medical's active insiders?: Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.
Are insiders buying or selling shares of Shockwave Medical?: In the last year, insiders at the sold shares 21 times. They sold a total of 129,216 shares worth more than $30,809,995.81. The most recent insider tranaction occured on March, 26th when Director Laura Francis sold 1,500 shares worth more than $450,000.00. Insiders at Shockwave Medical own 3.4% of the company. Learn More about insider trades at Shockwave Medical.
Information on this page was last updated on 3/26/2024.

Dan Puckett Insider Trading History at Shockwave Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2024	Sell	3,406	$229.76	$782,562.56	27,732
12/8/2023	Sell	200	$173.88	$34,776.00	28,784
5/11/2023	Sell	2,050	$291.95	$598,497.50	29,398
4/19/2023	Sell	1,002	$264.67	$265,199.34	31,658
3/20/2023	Sell	1,100	$200.74	$220,814.00	33,658
2/21/2023	Sell	1,100	$192.84	$212,124.00	41,158
2/2/2023	Sell	2,073	$190.25	$394,388.25	41,158
1/20/2023	Sell	1,100	$177.45	$195,195.00	39,938
12/20/2022	Sell	1,100	$212.93	$234,223.00	39,938
11/21/2022	Sell	1,100	$246.96	$271,656.00	39,938
10/20/2022	Sell	1,100	$268.35	$295,185.00	39,938
9/20/2022	Sell	1,100	$291.33	$320,463.00	39,938
8/22/2022	Sell	1,100	$292.21	$321,431.00	39,938
7/20/2022	Sell	1,350	$207.09	$279,571.50	39,938
6/21/2022	Sell	1,350	$161.40	$217,890.00	39,938
5/20/2022	Sell	1,350	$161.38	$217,863.00	41,048
4/19/2022	Sell	3,691	$200.59	$740,377.69	39,938
2/22/2022	Sell	6,621	$144.71	$958,124.91
1/20/2022	Sell	1,500	$146.49	$219,735.00
12/20/2021	Sell	2,700	$168.73	$455,571.00
11/1/2021	Sell	2,500	$219.72	$549,300.00
10/1/2021	Sell	2,500	$195.47	$488,675.00
9/1/2021	Sell	2,500	$216.93	$542,325.00
8/2/2021	Sell	2,500	$176.29	$440,725.00
7/1/2021	Sell	2,500	$189.55	$473,875.00
6/1/2021	Sell	2,500	$178.66	$446,650.00	46,129
5/3/2021	Sell	2,500	$158.22	$395,550.00	46,130
4/21/2021	Sell	5,000	$149.20	$746,000.00	50,788
4/19/2021	Sell	1,391	$137.28	$190,956.48	46,897
4/16/2021	Sell	1,109	$138.71	$153,829.39	46,897
3/1/2021	Sell	2,000	$122.91	$245,820.00	51,570
2/1/2021	Sell	2,000	$117.68	$235,360.00	37,649
1/4/2021	Sell	2,000	$102.35	$204,700.00	37,650
12/1/2020	Sell	2,000	$94.36	$188,720.00	37,649
11/10/2020	Sell	10,000	$84.75	$847,500.00	42,677
11/2/2020	Sell	2,000	$67.44	$134,880.00	37,650
10/15/2020	Sell	12,000	$74.30	$891,600.00	37,649
8/24/2020	Sell	527	$60.00	$31,620.00	37,835
8/21/2020	Sell	3,866	$60.02	$232,037.32	42,112
8/4/2020	Sell	1,430	$50.01	$71,514.30	45,878
2/14/2020	Sell	50,000	$44.25	$2,212,500.00	58,000
9/9/2019	Sell	75,000	$34.71	$2,603,250.00

Dan Puckett Buying and Selling Activity at Shockwave Medical

Shockwave Medical Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Today's Range

Now: $334.75

$334.75

50 Day Range

MA: $332.85

$328.87

$334.83

2 Week Range

Now: $334.75

$157.00

$334.90

Volume

N/A

Average Volume

968,088 shs

Market Capitalization

$12.57 billion

P/E Ratio

78.21

Dividend Yield

N/A

Beta

0.88

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.